This study demonstrated in a retrospective Canadian cohort that AR is expressed by IHC in the majority of breast cancer BrM, and that HER2+ BrM most frequently expressed AR, while TNBC BrM least frequently expressed AR. Here, ERBB2 is linked to breast carcinoma.